Jazz Pharmaceuticals Announces Third Quarter 2009 Financi...(Selling general and administrative ...),Health

Date:11/5/2009

Selling, general and administrative 15,061 24,329 42,934 91,218 Amortization of intangible assets 2,057 3,487 5,611 9,454 ----- ----- ----- ----- Total operating expenses 27,100 45,490 85,645 166,565 ------ ------ ------ ------- Income (loss) from operations 3,709 (27,744) 4,520 (118,646) Interest income 2 353 29 1,700 Interest expense (5,384) (5,355) (17,034) (14,377) Other income (expense), net 1 19 (4) 6 Gain on sale of product rights - 3,918 - 3,918 - ----- - ----- Net loss $(1,672) $(28,809) $(12,489) $(127,399) ======= ======== ======== ========= Net loss per share: Basic and diluted $(0.05) $(1.07) $(0.42) $(5.12) ====== ====== ====== ====== Weighted-average common shares used in computing net loss per share: Basic and diluted 30,895 27,025 29,635 24,895 ====== ====== ====== ====== JAZZ PHARMACEUTICALS, INC. SUMMARY OF PRODUCT SALES, NET (In thousands) (Unaudited) Three Months Nine Months Ended Ended September 30, September 30, -------------- -------------- 2009 2008 2009 2008 ---- ---- ---- ---- Xyrem
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate